Janssen Vaccine Technologies
Source video: Janssen’s PER.C6® cell line and AdVac® technology: Janssen Global1
OUR INNOVATIVE VACCINE TECHNOLOGY PLATFORMS – ADVAC® AND PER.C6®
Our innovative vaccine technology platforms –AdVac® and PER.C6® – offer real hope for the accelerated development of vaccines and are designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks.1,2
These are the same technologies that were used in the development and manufacturing of our investigational Ebola vaccine, which is has been used in the Democratic Republic of the Congo (DRC) and Rwanda, and were also used to construct our Zika, RSV and HIV vaccine candidates.1,3-5
The SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® and PER.C6® technologies in an effort to help combat the current COVID-19 pandemic.2
This technology provides a cost-effective manufacturing system for high-yield, faster and large-scale production of vaccines and monoclonal antibodies.
It is especially useful for vaccine manufacturing that requires the production of hard-to-grow viruses and could hold the key to making such vaccines affordable for the whole world.
A technology based on the development and production of adenovirus vectors (gene carriers).
It can be used together with PER.C6® technology to develop recombinant vaccines against life-threatening infectious diseases.
Janssen. Janssen Vaccine Technologies. Available at https://www.janssen.com/infectious-diseases-and-vaccines/vaccine-technologies. Last accessed May 2020
Johnson & Johnson. Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine. Available at: https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine. Last accessed May 2020.
Johnson & Johnson. Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production. Available at: https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-major-commitment-to-speed-ebola-vaccine-development-and-significantly-expand-production. Last accessed May 2020.
Johnson & Johnson. Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine. Available at: https://www.jnj.com/johnson-johnson-announces-new-public-private-partnership-to-support-first-phase-3-efficacy-study-of-janssens-investigational-prophylactic-hiv-vaccine. Last accessed May 2020.
Johnson & Johnson. Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults. Available at: https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-for-investigational-prophylactic-vaccine-for-the-prevention-of-respiratory-syncytial-virus-in-older-adults. Last accessed May 2020.